Therapeutic potential of protease-activated receptor-1 antagonists

Expert Opinion on Investigational Drugs

Volumn 12, Issue 2, 2003, Pages 209-221

  Derian, Claudia K ^a   Maryanoff, Bruce E ^a   Zhang, Han Cheng ^a   Andrade Gordon, Patricia ^a  

^a Drug Discovery   (United States)

Author keywords

Platelets; Protease activated receptor; Thrombin; Vascular

Indexed keywords

CYTOKINE; FR 171113; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; ISOXAZOLE 54; ISOXAZOLE DERIVATIVE; N CINNAMOYL 4 FLUOROPHENYL 4 GUANIDINOPHENYLLEUCYLARGINYLAMINE; N CINNAMOYL 4 FLUOROPHENYL 4 GUANIDINOPHENYLLEUCYLARGINYLARGINYLAMINE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; RECEPTOR BLOCKING AGENT; RWJ 56110; RWJ 56117; RWJ 58259; SCH 328725; SCH 79797; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; CELL PROLIFERATION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME SYNTHESIS; HEART MUSCLE; HEMOSTASIS; HUMAN; LIPID METABOLISM; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SECRETION; RESTENOSIS; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; TISSUE INJURY; VASCULARIZATION;

ANIMALS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HUMANS; ORGAN SPECIFICITY; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; THROMBIN;

EID: 0037312963     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.2.209     Document Type: Review

References (101)

1. YUSUF S, REDDY S, OUNPUU S, ANAND S: Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation (2001) 104:2746-2753.
2. YUSUF S, REDDY S, OUNPUU S, ANAND S: Global burden of cardiovascular diseases: Part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation (2001) 104:2855-2864.
3. CHESEBRO JH, WEBSTER MW, ZOLDHELYI P, ROCHE PC, BADIMON L, BADIMON JJ: Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. Circulation (1992) 86:III100-III110.
4. TURPIE AGG: Clinical potential of antithrombotic drugs in coronary syndromes. Am. J. Cardiol. (1998) 82:11L-14L.
5. WEITZ JI, BULLER HR: Direct thrombin inhibitors in acute coronary syndromes: Present and future. Circulation (2002) 105:1004-1011.
6. MACFARLANE SR, SEATTER MJ, KANKE T, HUNTER GD, PLEVIN R: Proteinase-activated receptors. Pharmacol. Rev. (2001) 53:245-282.
7. VERGNOLLE N, WALLACE JL, BUNNETT NW, HOLLENBERG MD: Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol. Sci. (2001) 22:146-152.
8. DERIAN CK, DAMIANO BP, D'ANDREA MR, ANDRADE-GORDON P: Thrombin regulation of cell function through protease-activated receptors: Implications for therapeutic intervention. Biochemistry (Moscow) (2002) 67:56-64.
9. HOLLENBERG MD, COMPTON SJ: International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol. Rev. (2002) 54:203-217.
10. VU TKH, HUNG DT, WHEATON VI, COUGHLIN SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell (1991) 64:1057-1068.
11. RASMUSSEN UB, VOURET-CRAVIARI V, JALLAT S et al.: cDNA cloning and expression of a hamster α-thrombin receptor coupled to calcium mobilization. FEBS Lett. (1991) 288:123-128.
12. ZHONG C, HAYZER DJ, CORSON MA, RUNGE MS: Molecular cloning of the rat vascular smooth muscle thrombin receptor. Evidence for in vitro regulation by basic fibroblast growth factor. J. Biol Chem. (1992) 267:16975-16979.
13. NANEVICZ T, ISHII M, WANG L et al.: Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site. J. Biol. Chem. (1995) 270:21619-21625.
14. BEAVERS MP, MARYANOFF BE, NGUYEN D, BLACKHART BD: A theoretical model of the human thrombin receptor (PAR-1), the first known protease-activated G-protein-coupled receptor. Adv. Med. Chem. (1999) 4:245-271.
15. BLACKHART BD, RUSLIM-LITRUS L, LU C-C et al.: Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol. Pharmacol. (2000) 58:1178-1187.
16. HAMMES SR, SHAPIRO MJ, COUGHLIN SR: Shutoff and agonist-triggered internalization of protease-activated receptor 1 can be separated by mutation of putative phosphorylation sites in the cytoplasmic tail. Biochemistry (1999) 38:9308-9316.
17. TREJO J, ALTSCHULER Y, FU H-W, MOSTOV KE, COUGHLIN SR: Protease-activated receptor-1 down-regulation. A mutant HeLa cell fine suggests novel requirements for PAR1 phosphorylation and recruitment to clathrin-coated pits. J. Biol. Chem. (2000) 275:31255-31265.
18. NYSTEDT S, EMILSSON K, WAHLESTEDT C, SUNDELIN J: Molecular cloning of a potential proteinase activated receptor. Proc. Natl. Acad. Sci. USA (1994) 91:9208-9212.
19. NYSTEDT S, EMILSSON K, LARSSON A-K, STROEMBECK B, SUNDELIN J: Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur. J. Biochem. (1995) 232:84-89.
20. BOHM SK, KONG W, BROMME D et al.: Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem. J. (1996) 314:1009-1016.
21. ISHIHARA H, CONNOLLY AJ, ZENG D et al.: Protease-activated receptor 3 is a second thrombin receptor in humans. Nature (1997) 386:502-506.
22. KAHN ML, ZHENG Y-W, HUANG W et al.: A dual thrombin receptor system for platelet activation. Nature (1998) 394:690-694.
23. XU WF, ANDERSEN H, WHITMORE TE et al.: Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. USA (1998) 95:6642-6646.
24. BLACKHART BD, EMILSSON K, NGUYEN D et al.: Ligand cross-reactivity within the protease-activated receptor family. J. Biol. Chem. (1996) 271:16466-16471.
25. NISHIKAWA H, KAWABATA A, KAWAI K, KURODA R: Guinea pig platelets do not respond to GYPGKF, a protease-activated receptor-4-activating peptide: A property distinct from human platelets. Blood Coagulation Fibrinolysis (2000) 11:111-113.
26. ANDRADE-GORDON P, DERIAN CK, MARYANOFF BE et al.: Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. (2001) 298:34-42.
27. MIRZA H, SCHMIDT VA, DERIAN CK, JESTY J, BAHOU WF: Mitogenic responses mediated through the proteinase-activated receptor-2 are induced by expressed forms of mast cell α- or β-tryptases. Blood (1997) 90:3914-3922.
28. CORVERA CU, DERY O, MCCONALOGUE K et al.: Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. J. Clin. Invest. (1997) 100:1383-1393.
29. KAHN ML, NAKANISHI-MATSUI M, SHAPIRO MJ, ISHIHARA H, COUGHLIN SR: Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. (1999) 103:879-887.
30. CONNOLLY AJ, ISHIHARA H, KAHN ML, FARESE RV Jr, COUGHLIN SR: Role of the thrombin receptor in development and evidence for a second receptor. Nature (1996) 381:516-519.
31. DARROW AL, FUNG-LEUNG WP, YE RD et al.: Biological consequences of thrombin receptor deficiency in mice. Thromb. Haemostasis (1996) 76:860-866.
32. GRIFFIN CT, SRINIVASAN Y. ZHENG Y-W, HUANG W, COUGHLIN SR: A role for thrombin receptor signaling in endothelial cells during embryonic development. Science (2001) 293:1666-1670.
33. SCHMIDT VA, NIERMAN WC, MAGLOTT DR et al.: The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets. J. Biol. Chem. (1998) 273:15061-15068.
34. NAKANISHI-MATSUI M, ZHENG Y-W, SULCINER DJ, WEISS EJ, LUDEMAN MJ, COUGHLIN SR: PAR3 is a cofactor for PAR4 activation by thrombin. Nature (2000) 404:609-613.
35. SAMBRANO GR, WEISS EJ, ZHENG YW, HUANG W, COUGHLIN SR: Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature (2001) 413:74-78.
36. GARCIA JGN: Molecular mechanisms of thrombin-induced human and bovine endothelial cell activation. J. Lab. Clin. Med. (1992) 120:513-519.
37. LUM H, ANDERSEN TT, SIFLINGER-BIRNBOIM A et al.: Thrombin receptor peptide inhibits thrombin-induced increase in endothelial permeability by receptor desensitization. J. Cell Biol. (1993) 120:1491-1499.
38. SUGAMA Y, TIRUPPATHI C, JANAKIDEVI K, ANDERSEN TT, FENTON JW 2nd, MALIK AB: Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: A mechanism for stabilizing neutrophil adhesion. J. Cell Biol. (1992) 119:935-944.
39. SHANKAR R, DE LA MOTTE CA, DICORLETO PE: 3-Deazaadenosine inhibits thrombin-stimulated platelet-derived growth factor production and endothelial-leukocyte adhesion molecule-1-mediated monocytic cell adhesion in human aortic endothelial cells. J. Biol. Chem. (1992) 267:9376-9382.
40. TSOPANOGLOU NE, PIPILI-SYNETOS E, MARAGOUDAKIS ME: Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am. J. Physiol (1993) 264:C1302-C1307.
41. HARALABOPOULOS GC, GRANT DS, KLEINMAN HK, MARAGOUDAKIS ME: Thrombin promotes endothelial cell alignment in matrigel in vitro and angiogenesis in vivo. Am. J. Physiol (1997) 273:C239-C245.
42. COLOTTA F, SCIACCA FL, SIRONI M, LUINI W, RABIET MJ, MANTOVANI A: Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin.Am. J. Pathol. (1994) 144:975-985.
43. CHI L, LI Y, STEHNO-BITTEL L et al.: Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J. Interferon Cytokine Res. (2001) 21:231-240.
44. KU DD, ZALESKI JK: Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J. Cardiovasc. Pharmacol. (1993) 22:609-616.
45. EMORI T, HIRATA Y, IMAI T et al.: Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell. Biochem. Pharmacol. (1992) 44:2409-2411.
46. GARCIA JGN, PATTERSON C, BAHLER C, ASCHNER J, HART CM, ENGLISH D: Thrombin receptor activating peptides induce calcium mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. J. Cell. Physiol. (1993) 156:541-549.
47. O'BRIEN PJ, PREVOST N, MOLINO M et al.: Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J. Biol. Chem. (2000) 275:13502-13509.
48. HAMILTON JR, FRAUMAN AG, COCKS TM: Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ. Res. (2001) 89:92-98.
49. STOUFFER GA, SAREMBOCK IJ, MCNAMARA CA, GIMPLE LW, OWENS GK: Thrombin-induced mitogenesis of vascular SMC is partially mediated by autocrine production of PDGF-AA. Am. J. Physiol. (1993) 265:C806-C811.
50. STOUFFER GA, RUNGE MS: The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells. Semin. Thromb. Hemostasis (1998) 24:145-150.
51. GALIS ZS, KRANZHOFER R, FENTON JW 2nd, LIBBY P: Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. (1997) 17:483-489.
52. ABBAGH K, LAURENT GJ, MCANULTY RJ, CHAMBERS RC: Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. Thromb. Haemostasis (1998) 79:405-409.
53. ANDRADE-GORDON P, MARYANOFF BE, DERIAN CK et al.: Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl. Acad. Sci. USA (1999) 96:12257-12262.
54. AHN HS, FOSTER C, BOYKOW G, STAMFORD A, MANNA M, GRAZIANO M: Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo [3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem. Pharmacol. (2000) 60:1425-1434.
55. MURAMATSU I, LANIYONU A, MOORE GJ, HOLLENBERG MD: Vascular actions of thrombin receptor peptide. Can. J. Physiol. Pharmacol. (1992) 70:996-1003.
56. ANTONACCIO MJ, NORMANDIN D, SERAFINO R, MORELAND S: Effects of thrombin and thrombin receptor activating peptides on rat aortic vascular smooth muscle. J. Pharmacol. Exp. Ther. (1993) 266:125-132.
57. CHEUNG W-M, ANDRADE-GORDON P, DERIAN CK, DAMIANO BP: Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo. Can. J. Physiol. Pharmacol. (1998) 76:16-25.
58. GLEMBOTSKI CC, IRONS CE, KROWN KA, MURRAY SF, SPRENKLE AB, SEI CA: Myocardial α-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J. Biol. Chem. (1993) 268:20646-20652.
59. JIANG T, KUZNETSOV V, PAK E, ZHANG H, ROBINSON RB, STEINBERG SF: Thrombin receptor actions in neonatal rat ventricular myocytes. Circ. Res. (1996) 78:553-563.
60. SABRI A, MUSKE G, ZHANG H et al.: Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ. Res. (2000) 86:1054-1061.
61. KU DD: Unmasking of thrombin vasoconstriction in isolated perfused dog hearts after intracoronary infusion of air embolus. J. Pharmacol. Exp. Ther. (1987) 243:571-576.
62. DAMIANO BP, MITCHELL JA, CHEUNG W-M, FALOTICO R: Activation of vascular thrombin receptors mediates cardiac response to alpha-thrombin in isolated, perfused guinea pig heart. Am. J. Physiol. (1996) 270:H1585-H1596.
63. RAZIN E, MARX G: Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J. Immunol. (1984) 133:3282-3285.
64. STRUKOVA SM, DUGINA TN, KHLGATIAN SV, REDKOZUBOV AE, REDKOZUBOVA GP, PINELIS VG: Thrombin-mediated events implicated in mast cell activation. Sem. Thromb. Hemostasis (1996) 22:145-150.
65. HE S, WALLS AF: Human mast cell tryptase: A stimulus of microvascular leakage and mast cell activation. Eur. J. Pharmacol. (1997) 328:89-97.
66. GALLI SJ: Mast cells and basophils. Curr. Opin. Hematol. (2000) 7:32-39.
67. D'ANDREA MR, ROGAHN CJ, ANDRADE-GORDON P: Localization of protease-activated receptors - 1 and -2 in human mast cells: Indications for an amplified mast cell degranulation cascade. Biotech. Histochem. (2000) 75:85-90.
68. HOFFMAN M, COOPER ST: Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. Blood Cells Mol. Dis. (1995) 21:156-167.
69. TORDAI A, FENTON JW, II, ANDERSEN T, GELFAND EW: Functional thrombin receptors on human T lymphoblastoid cells. J. Immunol. (1993) 150:4876-4886.
70. JOYCE DE, CHEN Y, ERGER RA, KORETZKY GA, LENTZ SR: Functional interactions between the thrombin receptor and the T-cell antigen receptor in human T-cell lines. Blood (1997) 90:1893-1901.
71. DAMIANO BP, CHEUNG W-M, MITCHELL JA, FALOTICO R: Cardiovascular actions of thrombin receptor activation in vivo. J. Pharmacol. Exp. Ther. (1996) 279:1365-1378.
72. WILCOX JN, RODRIGUEZ J, SUBRAMANIAN R et al.: Characterization of thrombin receptor expression during vascular lesion formation. Circ. Res. (1994) 75:1029-1038.
73. GUITTENY A-F, HERBERT J-M: Failure of heparin to inhibit the expression of the thrombin receptor following endothelial injury of the rabbit carotid artery. Eur. J. Pharmacol. (1997) 327:157-162.
74. CHEUNG W-M, D'ANDREA MR, ANDRADE-GORDON P, DAMIANO BP: Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler. Thromb. Vasc. Biol. (1999) 19:3014-3024.
75. CIRINO G, CICALA C, BUCCI MR, SORRENTINO L, MARAGANORE JM, STONE SR: Thrombin functions as an inflammatory mediator through activation of its receptor. J. Exp. Med. (1996) 183:821-827.
76. VERGNOLLE N, HOLLENBERG MD, WALLACE JL: Pro- and anti-inflammatory actions of thrombin: A distinct role for proteinase-activated receptor-1 (PAR1). Br. J. Pharmacol. (1999) 126:1262-1268.
77. DE GARAVILLA L. VERGNOLLE N, YOUNG SH et al.: Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br. J. Pharmacol. (2001) 133:975-987.
78. WEISS EJ, HAMILTON JR, LEASE KE, COUGHLIN SR: Protection against thrombosis in mice lacking PAR3. Blood (2002) 100:3240-3244.
79. AHN H-S, CHACKALAMANNIL S: Nonpeptide thrombin receptor antagonists. Drug Future (2001) 26:1065-1085.
80. ANDERLUH M, DOLENC MS: Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. Curr. Med. Chem. (2002) 9:1229-1250.
81. FURMAN MI, LIU L, BENOIT SE, BECKER RC, BARNARD MR, MICHELSON AD: The cleaved peptide of the thrombin receptor is a strong platelet agonist. Proc. Natl. Acad. Sci. USA (1998) 95:3082-3087.
82. HASAN AAK, AMENTA S, SCHMAIER AH: Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation (1996) 94:517-528.
83. HASAN AAK, REBELLO SS, SMITH E et al.: Thrombostatin inhibits induced canine coronary thrombosis. Thromb. Haemostasis (1999) 82:1182-1187.
84. CONNOLLY TM, CONDRA C, FENG D-M et al.: Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb. Haemostasis (1994) 72:627-633.
85. DERIAN CK, SANTULLI RJ, TOMKO KA, HAERTLEIN BJ, ANDRADE-GORDON P: Species differences in platelet responses to thrombin and SFLLRN. Receptor-mediated calcium mobilization and aggregation, and regulation by protein kinases. Thromb. Res. (1995) 78:505-519.
86. BAHOU WF, COLLER BS, POTTER CL, NORTON KJ, KUTOK JL, GOLIGORSKY MS: The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. J. Clin. Invest. (1993) 91:1405-1413.
87. COOK JJ, SITKO GR, BEDNAR B et al.: An antibody against the exo-site of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation (1995) 91:2961-2971.
88. PAKALA R, LIANG TC, BENEDICT CR: A peptide ligand of the human thrombin receptor antagonizes thrombin receptor activating peptide and alpha-thrombin-induced platelet aggregation. Fibrinolysis Proteolysis (2000) 14:15-21.
89. BERNATOWICZ MS, KLIMAS CE, HARTL KS, PELUSO M, ALLEGRETTO NJ, SEILER SM: Development of potent thrombin receptor antagonist peptides. J. Med. Chem. (1996) 39:4879-4887.
90. KAWABATA A, SAIFEDDINE, M. ALANI B, LEBLOND L, HOLLENBERG MD: Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1-targeted ligands. J. Pharmacol. Exp. Ther. (1999) 288:358-370.
91. ZHANG HC, DERIAN CK, ANDRADE-GORDON P et al.: Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: Potent, selective peptide mimetics based on indole and indazole templates. J. Med. Chem. (2001) 44:1021-1024.
92. KATO Y, KITA Y, NISHIO M et al.: In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur. J. Pharmacol. (1999) 384:197-202.
93. AHN H-S, ARIK L, BOYKOW G et al.: Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg. Med. Chem. Lett. (1999) 9:2073-2078.
94. CHACKALAMANNIL S, DOLLER D, EAGEN K et al.: Potent, low molecular weight thrombin receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2851-2853.
95. BARROW JC, NANTERMET PG, SELNICK HG et al.: Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2691-2696.
96. NANTERMET PG, BARROW JC, LUNDELL GF et al.: Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1). Bioorg. Med. Chem. Lett. (2002) 12:319-323.
97. GILCHRIST A, VANHAUWE JF, LI A, THOMAS TO, VOYNO-YASENETSKAYA T, HAMM HE: Gα minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin-mediated endothelial activation. J. Biol. Chem. (2001) 276:25672-25679.
98. COVIC L, GRESSER AL, TALAVERA J, SWIFT S, KULIOPULOS A: Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. USA (2002) 99:643-648.
99. DERIAN CK, DAMIANO BP, ADDO MF et al.: Blockade of the thrombin receptor protease-activated receptor-1 (PAR-1) with a small-molecule antagonist prevents thrombus formation and vascular occlusion in non-human primates. J. Pharmacol. Exp. Ther. (In Press).
100. HERBERT JM, GUY AF, LAMARCHE I, MARES AM, SAVI P, DOL F: Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide. J. Cell. Physiol. (1997) 170:106-114.
101. TAKADA M, TANAKA H, YAMADA T et al.: Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ. Res. (1998) 82:980-987.